Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial

被引：0
|
作者：
Mease, Philip J. [1 ,2 ]
Kavanaugh, Arthur [3 ]
Reimold, Andreas [4 ,5 ]
Tahir, Hasan [6 ]
Rech, Juergen [7 ]
Hall, Stephen [8 ]
Geusens, Piet [9 ,10 ]
Pascale, Pellet [11 ]
Delicha, Evie Maria [11 ]
Pricop, Luminita [12 ]
Mpofu, Shephard [11 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] UC San Diego Sch Med, La Jolla, CA USA
[4] Dallas VA Med Ctr, Dallas, TX USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[6] Barts Hlth NHS Trust, London, England
[7] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[8] Monash Univ, Melbourne, Vic, Australia
[9] Univ Hasselt, Hasselt, Belgium
[10] Maastricht Univ Hosp, Maastricht, Netherlands
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
961
引用
收藏
页数：3
相关论文
共 50 条
  • [31] . SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Ricardo
    Cohen, Martin
    RHEUMATOLOGY, 2017, 56 : 94 - 94
  • [32] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Zuazo, J.
    Readie, A.
    Porter, B.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 812 - 813
  • [33] Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
    Gossec, Laure
    Kvien, Tore K.
    Conaghan, Philip G.
    Ostergaard, Mikkel
    Canete, Juan D.
    Gaillez, C.
    Mpofu, Shephard
    Sherif, Bintu
    Jugl, Steffen
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [34] Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies
    Ogdie, Alexis
    Gladman, Dafna
    Coates, Laura
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3812 - 3815
  • [35] SECUKINUMAB PROVIDES CLINICAL IMPROVEMENTS IN PATIENTS WITH ACTIVE OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM A POOLED ANALYSIS OF FIVE PHASE 3 STUDIES
    Coates, Laura C.
    Ogdie, Alexis
    Gladman, Dafna D.
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip J.
    RHEUMATOLOGY, 2022, 61
  • [36] Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pellet, Pascale
    Delicha, Evie Maria
    Mpofu, Shephard
    Pricop, Luminita
    RMD OPEN, 2018, 4 (02):
  • [37] Secukinumab provides sustained improvement in signs and symptoms in active psoriatic arthritis up-to 3 years: Data from FUTURE1 and FUTURE2 studies
    Nash, P.
    Gottlieb, A. Bendix
    McInnes, I.
    Mease, P.
    Delicha, E. M.
    Pellet, P.
    Kajekar, R.
    Pricop, L.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 88 - 88
  • [38] SECUKINUMAB SUSTAINS IMPROVEMENTS IN SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 2 YEARS (FUTURE 4)
    Everding, A.
    Kivitz, A.
    Nash, P.
    Tahir, H.
    Pellet, P.
    Wang Yi
    Pricop, L.
    Abrams, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 727 - 728
  • [39] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE-2)
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Martin, R.
    Readie, A.
    Richards, H.
    Porter, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 783 - 783
  • [40] Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
    Baraliakos, Xenofon
    Gossec, Laure
    Pournara, Effie
    Jeka, Slawomir
    Blanco, Ricardo
    D'Angelo, Salvatore
    Schett, Georg
    Schulz, Barbara
    Rissler, Michael
    Whyms, Dermot
    Perella, Chiara
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345